Larimar Therapeutics Inc

NASDAQ:LRMR   3:59:50 PM EDT
2.68
-0.02 (-0.74%)
Earnings Announcements

Larimar Therapeutics Reports Fourth Quarter And Full Year 2021 Operating And Financial Results

Published: 03/25/2022 11:14 GMT
Larimar Therapeutics Inc (LRMR) - Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results.
Q4 Loss per Share $0.50.
As of December 31, 2021, Company Had Cash and Cash Equivalents Totaling $70.1 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.57

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.